Preparation of mGM-CSF/βhCG fusion protein and the effect of its sensitized DC vaccine on RM-1 prostate tumor in mice
10.11665/j.issn.1000-5048.20150117
- VernacularTitle:mGM-CSF/βhCG融合蛋白的制备及其致敏树突状细胞疫苗抗小鼠RM-1前列腺癌的作用
- Author:
Rongyue CAO
1
;
Na CHANG
;
Manman LI
;
Yunkang WANG
;
Di WU
;
Baoying SHI
;
Yuting YUAN
;
Jun LONG
Author Information
1. 中国药科大学微基因药学实验室
- Publication Type:Journal Article
- Keywords:
βhCG;
mGM-CSF;
antitumor;
prostate cancer;
fusion protein;
immunotherapy;
dendritic cells
- From:
Journal of China Pharmaceutical University
2015;46(1):111-116
- CountryChina
- Language:Chinese
-
Abstract:
An expression vector pET-28a-mGM-CSF-X10-βhCGCTP37 plasmid containing the βhCG and mGM-CSF gene was designed and constructed. The fusion protein was induced by lactose and purified by ammonium sulfate precipitation and DEAE-cellulose anion exchange column. Then dendritic cells(DC)in C57BL/6J mice were extracted and sensitized by the fusion protein to obtain DC vaccine. The DC vaccine was inoculated to C57BL of / 6J mice with prostate cancer RM-1. The results indicated that the anti-tumor effects of DC group and DC combined with paclitaxel(DP)group were superior to that of paclitaxel(Pac)group(P< 0. 01), and the anti-tumor effect of DP group was better than that of DC group. Thus, the constructed DC vaccine can inhibit the growth of prostate cancer, and have synergistic anti-tumor when used with paclitaxel.
